These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38904277)

  • 1. Brigatinib in
    Plotkin SR; Yohay KH; Nghiemphu PL; Dinh CT; Babovic-Vuksanovic D; Merker VL; Bakker A; Fell G; Trippa L; Blakeley JO;
    N Engl J Med; 2024 Jun; 390(24):2284-2294. PubMed ID: 38904277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
    Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
    J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?
    Seppälä MT; Sainio MA; Haltia MJ; Kinnunen JJ; Setälä KH; Jääskeläinen JE
    J Neurosurg; 1998 Jul; 89(1):36-41. PubMed ID: 9647170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
    Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
    J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
    Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
    J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
    Plotkin SR; Allen J; Dhall G; Campian JL; Clapp DW; Fisher MJ; Jain RK; Tonsgard J; Ullrich NJ; Thomas C; Edwards LJ; Korf B; Packer R; Karajannis MA; Blakeley JO
    Neuro Oncol; 2023 Aug; 25(8):1498-1506. PubMed ID: 37010875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
    Sun S; Liu A
    J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
    Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
    J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
    J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of multiple tumors in neurofibromatosis type 2 patients.
    Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
    Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
    Goutagny S; Raymond E; Esposito-Farese M; Trunet S; Mawrin C; Bernardeschi D; Larroque B; Sterkers O; Giovannini M; Kalamarides M
    J Neurooncol; 2015 Apr; 122(2):313-20. PubMed ID: 25567352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
    Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
    Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
    Sponghini AP; Platini F; Rondonotti D; Soffietti R
    Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth Dynamics of Intracranial Tumors in Patients with Neurofibromatosis Type 2.
    Lawson McLean AC; Rosahl SK
    World Neurosurg; 2017 Feb; 98():152-161. PubMed ID: 27777160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
    Plotkin SR; Halpin C; McKenna MJ; Loeffler JS; Batchelor TT; Barker FG
    Otol Neurotol; 2010 Sep; 31(7):1135-43. PubMed ID: 20736812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
    Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
    Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.